← back to search

Michael Hogarth

University of California San Diego · US
Area of research
Health Information Management · Molecular Biology
Research interest
Research interests include Electronic Health Records Systems, Biomedical Text Mining and Ontologies, Global Cancer Incidence and Screening, and Semantic Web and Ontologies.
h-index
22
citations
4,712
works
106
NIH funding
primary concept
email

Recent publications

Risk-Based vs Annual Breast Cancer Screening
JAMA 2025cited by 21position: middledoi
Large Language Models for More Efficient Reporting of Hospital Quality Measures
NEJM AI 2024cited by 45position: middledoi
Using Large Language Models to Support Content Analysis: A Case Study of ChatGPT for Adverse Event Detection
Journal of Medical Internet Research 2024cited by 23position: middledoi
Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum
JAMA Internal Medicine 2023cited by 2,202position: middledoi
Evaluating Artificial Intelligence Responses to Public Health Questions
JAMA Network Open 2023cited by 110position: middledoi
AI in Pathology: What could possibly go wrong?
Seminars in Diagnostic Pathology 2023cited by 72position: middledoi
Screen or No Screen? Lessons Learnt from a Real-World Deployment Study of Using Voice Assistants With and Without Touchscreen for Older Adults
2023cited by 24position: middledoi
Clinical Characteristics and Outcomes of Drug-Induced Acute Kidney Injury Cases
Kidney International Reports 2023cited by 22position: middledoi
The WISDOM study: a new approach to screening can and should be tested
Breast Cancer Research and Treatment 2021cited by 47position: middledoi
The WISDOM Study: breaking the deadlock in the breast cancer screening debate
npj Breast Cancer 2017cited by 279position: middledoi
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
New England Journal of Medicine 2016cited by 551position: middledoi
Adaptive Randomization of Neratinib in Early Breast Cancer
New England Journal of Medicine 2016cited by 458position: middledoi
Abstract CT042: Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Cancer Research 2016cited by 17position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Eric C. Leas · UC San Diego Health System3 papers (2023–2024)Mark Dredze · Johns Hopkins University3 papers (2023–2024)Davey M. Smith · Imperial College London3 papers (2023–2024)John W. Ayers · University of California System3 papers (2023–2024)Zechariah Zhu · University of California San Diego2 papers (2023–2023)Adam Poliak · New York University2 papers (2023–2023)Rishivardhan Krishnamoorthy · University of San Diego1 papers (2024–2024)Faisal Mahmood · Aga Khan University Hospital1 papers (2023–2023)Kimberly Quintero · University of San Diego1 papers (2024–2024)Yichen Han · Carnegie Mellon University1 papers (2023–2023)Aaron M. Goodman · Moores Cancer Center1 papers (2023–2023)Chen Chen · Florida International University1 papers (2023–2023)Chad VanDenBerg · UC San Diego Health System1 papers (2024–2024)Dibson Gondim · Indiana University School of Medicine1 papers (2023–2023)S. V. Joshi · South African Sugarcane Research Institute1 papers (2024–2024)Hayden Pour · UC San Diego Health System1 papers (2024–2024)Karandeep Singh · Stanford University1 papers (2024–2024)Shamim Nemati · University of California San Diego1 papers (2024–2024) · 1 papers (2023–2023)Arkajyoti Roy · The University of Texas at San Antonio1 papers (2023–2023)